Recent Updates
Recently added Catalysts
EXOZ Positive Sentiment

Bionity.com: EXOZ awarded $2M NIH grant to advance cannabinoid analogues for drug discovery

Friday, June 26, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: eXoZymes has secured a $2 million Phase IIB SBIR grant from the NIH to enhance the development of rare cannabinoids and novel cannabinoid analogs. The funding will support the expansion of their proprietary molecule library and optimize production over the next two years. This initiative aims to generate preclinical data and validate their technology for future pharmaceutical collaborations.
Price reaction · baseline $7.4 (2026-06-25 close) · hit pre-market · 1 other EXOZ headline(s) in the window, move may be shared
day 0 close
+8.5%
day 1
+13.8%
day 3 · peak
+14.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Awarded a significant $2 million grant from NIH.
  • Focus on developing rare cannabinoids and novel analogs.
  • Utilizing AI-enhanced biomanufacturing for drug discovery.
  • Potential for future pharmaceutical partnerships and licensing.

Full Press Release Details

Recap: On June 24, eXoZymes has been awarded a $2 million Phase IIB SBIR grant from the NIH to advance the development of rare cannabinoids and novel cannabinoid analogs for drug discovery. Over the next two years, the company will use its AI-enhanced, cell-free biomanufacturing platform to expand its library of proprietary molecules, optimize production, and generate preclinical data, further validating its technology while supporting future pharmaceutical partnership and licensing opportunities.

Frequently Asked Questions

What is the purpose of the NIH grant awarded to eXoZymes?

The $2 million grant aims to advance the development of rare cannabinoids and novel cannabinoid analogs for drug discovery.

How will eXoZymes utilize the grant funding?

The funding will be used to expand their library of proprietary molecules and optimize production.

What technology is eXoZymes using for drug discovery?

eXoZymes is using an AI-enhanced, cell-free biomanufacturing platform for their research.

What are the expected outcomes of this grant?

The project aims to generate preclinical data and validate their technology for future partnerships.

ShareAdd on Google
Tags: EXOZ Viatris Investor Conferences Healthcare eXoZymes NIH grant cannabinoids drug discovery biomanufacturing
Last updated: Jun 26, 2026

Biotech snapshot

Cash runway
$6M liquidity · $1M/mo burn
~10 mo
Medium dilution risk